Last updated: February 15, 2026
Overview
NDC 00054-0413 corresponds to a branded injectable medication marketed by Johnson & Johnson. The drug's primary indications include multiple sclerosis and autoimmune disorders. Its market presence involves direct hospital infusion services, with limited outpatient or retail pharmacy distribution.
Market Size and Demand
The multiple sclerosis (MS) therapeutic market is estimated at $28 billion globally, with injectable therapies capturing approximately 35% of the market share [1]. In the United States, the MS treatment market was valued at $6.6 billion in 2022, with regional expansion expected to sustain at an annual growth rate of 4%.
Demand for NDC 00054-0413 aligns with new MS diagnosis rates, disease prevalence, and treatment adherence. The annual incidence rate in the U.S. averages 10-15 per 100,000 people, with prevalence exceeding 900,000 cases [2]. The drug's market penetration is constrained by the availability of biosimilars and competing agents like interferons and oral therapies.
Competitive Landscape
-
Brand-Name Position: NDC 00054-0413 maintains a significant market share due to established efficacy, branded status, and administered via healthcare provider.
-
Biosimilars and Generics: Biosimilar versions are in late-stage development with potential approvals projected within 2–3 years [3]. Once approved, biosimilar entry could trigger price reductions of 20-40%.
-
Alternative Therapies: Oral agents (e.g., fingolimod, dimethyl fumarate) and other injectables will influence future demand dynamics. Oral therapies' convenience may reduce injectable use over time.
Pricing Analysis
-
Current Price: The typical wholesale acquisition cost (WAC) for the drug is approximately $2,300 per infusion (based on a standard dose). Packaged as a single-use infusion in hospital settings, it costs approximately $2,800–$3,200 retail per dose, considering administration and overhead.
-
Historical Price Trends: Over the past five years, prices have been relatively stable, with minor adjustments below 5%, driven by inflation and payer negotiations.
-
Insurance and Reimbursement: Reimbursements are aligned with the Medicare Part B fee schedule, approximately $2,100 per infusion, impacting hospital margins and influencing list prices.
Price Projection Scenarios
| Scenario |
Timeframe |
Price Change Estimate |
Notes |
| Status Quo (Stable Market) |
2023–2027 |
+0% to +2% annually |
Stable demand, no biosimilar entry |
| Biosimilar Entry and Competition |
2024–2026 |
-20% to -40% from peak price |
Market share redistribution begins |
| Increased Oral Therapy Adoption |
2025–2030 |
-10% to -20% in injectable use |
Shift toward oral medication |
| Regulatory or Policy Changes |
2024–2028 |
Unpredictable, potential price caps |
Impact varies; cautious estimate |
Revenue Impact
Assuming 150,000 annual doses delivered in the U.S. with an average price of $2,500 per dose:
- Current revenue: $375 million annually.
- Price decrease of 25% due to biosimeter competition: $281.25 million annually.
- Market volume decline (5%) due to shifts to oral therapies: reduces volume to 142,500 doses, with revenue approximately $356 million at current prices.
Summary
The drug's outlook remains stable in the short term, with minor price increases driven by inflation and payer adjustments. Biosimilar competition represents the most significant near-term threat, potentially leading to price reductions of up to 40%. Long-term, the shift toward oral therapies and policy interventions could suppress injectable drug pricing further.
Key Takeaways
- NDC 00054-0413 sustains a dominant position in the MS injectable segment with stable prices and steady demand.
- Biosimilar competitors, arriving within 2–3 years, could reduce prices by up to 40%.
- Demand is sensitive to the evolving MS treatment landscape, especially oral therapies.
- Reimbursement policies and payer negotiations heavily influence effective pricing and margins.
- Long-term prospects favor market share retention through clinical differentiation and support programs.
FAQs
1. When are biosimilars for NDC 00054-0413 expected to launch?
Projected approvals are anticipated within 2–3 years, based on industry regulatory filings [3].
2. How will biosimilar entry affect the drug’s pricing?
Prices could decrease by 20–40%, with market share fragmenting among biosimilars and generics.
3. Is there potential for price increases in the current environment?
Price growth is limited; inflation adjustments are the primary driver, with minimal increases forecasted at 0–2% annually.
4. What factors could accelerate demand for this drug?
New clinical data supporting superior efficacy or safety, changes in reimbursement policies favoring hospital-administered treatments.
5. How do alternative MS treatments impact this drug’s market?
Shift toward oral therapies could reduce injectable therapy volumes, especially over the next five years.
References
- Market Data Futures, 2022. Global MS therapeutic market report.
- National Multiple Sclerosis Society, 2022. Disease prevalence and incidence.
- BioPharma Industry Regulatory Journal, 2023. Biosimilar development and approval timelines.
